advisorsecurities master

ALZNAlzamend Neuro, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key
11630
Ticker
ALZN
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2021-06-15
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
ALZN

Detail

Enriched 2026-08-14 20:47

Market cap
$6,899,796
Shares outstanding (class)
4,791,525
Shares outstanding (weighted)
4,791,525
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
6
Location
ATLANTA, GA
Description

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data